Disease details

Clinical trials : 3,342 / Drugs : 2,355 - (DrugBank : 406) / Drug target genes : 269 - Drug target pathways : 241

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2012-005450-30-AT (EUCTR)	08/01/2014	11/11/2013	Investigation of neutralising antibodies against interferon-beta in patients with multiple sclerosis, in order to find markers to predict the development of these antibodies and minimize the risk of ineffective therapy	Anti-Biopharmaceutical Immunization: Prediction and analysis of clinical relevance to minimize the risk of immunization in multiple sclerosis patients on interferon-beta treatment - ABIRISK	Development of neutralising antibodies against Interferon-beta in the treatment of multiple sclerosis;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Avonex INN or Proposed INN: Interferon-beta 1a Other descriptive name: INTERFERON BETA -1A Trade Name: Rebif INN or Proposed INN: Interferon-beta 1a Other descriptive name: INTERFERON BETA -1A Trade Name: Betaferon INN or Proposed INN: Interferon-beta 1b Other descriptive name: INTERFERON BETA -1B Trade Name: Extavia INN or Proposed INN: Interferon-beta 1b Other descriptive name: INTERFERON BETA -1B Trade Name: Rebif INN or Proposed INN: Interferon-beta 1a Other descriptive name: INTERFERON BETA -1A Trade Name: Rebif INN or Proposed INN: Interferon-beta 1a Other descriptive name: INTERFERON BETA -1A	Medizinische Universität Innsbruck	NULL	Not Recruiting			Female: yes Male: yes	100	Phase 4	Austria;Sweden
2	NCT00490906 (ClinicalTrials.gov)	June 2007	21/6/2007	Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis	Comparison of Bone Effects With Copaxone and Interferon in Multiple Sclerosis: A Pilot Study	Multiple Sclerosis;Low Bone Density	Drug: Copaxone;Drug: Interferon-beta 1a;Drug: Interferon-beta 1b	Nancy Hammond, MD	Kansas City Area Life Sciences Institute, Inc.	Completed	18 Years	N/A	Female	60	N/A	United States
3	NCT00468182 (ClinicalTrials.gov)	April 2007	30/4/2007	Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis	Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis	Multiple Sclerosis	Drug: Interferon-beta 1b (Betaseron)	Rutgers, The State University of New Jersey	Bayer	Completed	18 Years	60 Years	Both	24		United States
4	NCT01111656 (ClinicalTrials.gov)	March 2007	15/3/2010	Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b	SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis - Follow up Study (SWABIMS Follow Up-study)	Relapsing-remitting Multiple Sclerosis	Drug: Interferon beta -1b group;Drug: Interferon beta -1b /Atorvastatin group	University Hospital Inselspital, Berne	Viollier AG, Basel, Switzerland;PharmaPart GmbH, Thalwil, Switzerland	Completed	18 Years	67 Years	Both	28	Phase 2	Switzerland
5	NCT00942591 (ClinicalTrials.gov)	May 2005	17/7/2009	Atorvastatin 40 mg in Patients With Relapsing-Remitting Multiple Sclerosis Treated With Interferon-Beta-1b	Efficacy, Safety and Tolerability of Atorvastatin 40 mg in Patients With Relapsing-remitting Multiple Sclerosis Treated With Interferon-beta-1b.SWiss Atorvastatin and Interferon-Beta 1b Trial In Multiple Sclerosis.	Multiple Sclerosis	Drug: Interferon beta 1b;Drug: Atorvastatin	University Hospital Inselspital, Berne	CRO: PharmaPart AG, Bahnhofstrasse 20, P.O. Box 173, CH-8800 Thalwil;Laboratory: Viollier AG Spalenring 145 / 147 Postfach 4002 Basel	Completed	18 Years	55 Years	Both	77	Phase 2	Switzerland